DOCSLIB.ORG

Generalized Bullous Fixed Drug Eruption After Influenza Vaccination

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Generalized Bullous Fixed Drug Eruption After Influenza Vaccination 450 Lettersto the Editor GeneralizedBullous Fixed Drug Eruption after In¯ uenza V accination,Simulating Bullous Pemphigoid I.GarcõÂa-Doval,E. RosoÂn,C.Feal,C. De laTorre, T. RodrõÂguezand M. J.Cruces Departmentof Dermatology, Complexo Hospitalario de P ontevedra,C /LuoreiroCrespo 2, E-36200,P ontevedra,Spain. E-mail:[email protected] AcceptedOctober 19, 2001. Sir, Severalcases of bullous pemphigoid appearing shortly after in¯uenza vaccination have been described ( 1±3 ).In one of thema relapsedeveloped after further vaccination one year later( 3).Toourknowledge, there is no previous description ofotherbullous diseases appearing after in¯ uenza vaccination. CASE REPORT A90-year-oldwoman was seen with a generalizedbullous eruption.She did not remember su Œeringfrom similar lesions previously.She had hypertension treated for more than one yearwith hydrochlorothiazide and valsartan (Co-diovan â ). Sixweeks before the start of cutaneous lesions, nimodipine (Nimotopâ )andginko biloba ( Tanakene â )hadbeen added toher therapy. In October 2000 she received an in¯ uenza vaccination.She denied intake of paracetamol or any other newdrug. Twelve hours after administration of the in¯ uenza vaccine,she noticed pruritus in her genital area and legs. Twenty-fourhours after the vaccination, well-demarcated erythematousmacules and large bullae appeared on these areas,and later on the trunk, hands and face ( Figs.1 and2 ). Somelesions had a darkercentre. She had oral and genital erosions.Systemic symptoms were absent. Suspecting the diagnosisof bullous pemphigoid, a cutaneousbiopsy was taken,and therapy was started with 30 mgof prednisone. Histologyof a skinlesion showed a prominentsubepidermal bullawith scarce perivascular mixed in¯ ammatory in® ltrates, focalhydropic degeneration of the basal layer, pigmentary incontinence,dyskeratotic keratinocytes with pyknotic nuclei inthe epidermis and papillary dermis, and areas of con¯ uent epidermalnecrosis. Direct and indirect immuno¯ uorescence Fig. 1. Erosions afterthe rupture of largebullae. werenegative. Ten days after its institution, prednisone and therest of hertherapy were withdrawn. Bullae disappeared in systemicsymptoms, the spontaneous resolution in 2 weeks 2weeks,and no new lesions had appeared after 10 months, withoutrecurrence ( butleaving persistent pigmented macules), butresidual pigmented macules persisted. She remained normo- andthe characteristic histology and negative immuno¯ uore- tensiveon alow-sodiumcontent diet. According to themanu- scence.The lack of a historyof previous localized lesions facturer,in¯ uenza vaccine ( Vacunaantigripal Pasteur â ) is an couldbe an argument against this diagnosis. However, in an inactivatedsubunit split vaccine that contains hemagglutinin, oldpatient with some cognitive disturbances minor lesions neuraminidase,and residual internal viral structural proteins, couldeasily remain unnoticed. Moreover, the diagnosis of aswell asthiomersal, formaldehyde, neomycin, phosphate ®xeddrug eruption can be madeon the ® rstepisode ( 4). buŒeredsaline and octoxinol-9. 2000-01serotypes were Generalizedbullous ® xeddrug eruption di Œerential A/Moscow/10/99 (H3N2), A/NewCaledonia /20/99 (H1N1) diagnosisincludes toxic epidermal necrolysis and bullous and B/Beijing/184/93.Standard patch tests, including all the pemphigoid.The ® nding,in some cases, of C3 and IgM components(except for octoxinol-9 ),andpatch test with the depositionalong the basement membrane during the early vaccine``as is’ ’,inpreviously a Œectedskin, gave negative phasesof ® xeddrug eruption, can make the distinction from results. bullouspemphigoid more di cult (5). Temporalcriteria led us to consider in¯ uenza vaccination asthe trigger of this patient eruption. The latent period after DISCUSSION thesupposed trigger for ® xeddrug eruption is characteristically We madethe diagnosis of generalized bullous ® xeddrug veryshort ( 5,6 ).In¯ uenza vaccination was the only drug eruptionon thebasis of theclinical picture of well-demarcated startedshortly before the eruption. Taking into account the polycycliclesions a Œectingthe face and mucosae, the lack of severityof her lesions, we consideredit unethical to perform Acta DermVenereol 81 Lettersto theEditor 451 aprovocationtest. The fact that patch testing was negative is notsurprising, as its sensitivity is low ( 7). Toour knowledge, this is the ® rstdescription of generalized bullous® xeddrug eruption after in¯ uenza vaccination. This di cult diŒerentialdiagnosis should always be taken into accountwhen describing bullous pemphigoid induced by vaccination,especially in relapsing cases. REFERENCES 1.Fournier B, DescampsV, BouscaratF, etal. Bullous pemphigoid inducedby vaccination.Br JDermatol1996; 135: 153± 154. 2.Lear JT, Tan BB, EnglishJS. Bullous pemphigoid following in¯uenza vaccination. Clin ExpDermatol 1996; 21: 392. 3.Downs AM,Lear JT, Bower CP, KennedyCT. Doesin¯ uenza vaccinationinduce bullous pemphigoid? A reportof fourcases. Br JDermatol1998; 138: 363. 4.Mahboob A, Haaron TS. Drugs causing ® xeddrug eruptions: a studyof 450cases. Int JDermatol1998; 37: 833± 838. 5.Hindsen M, ChristensenOB, Gruic V, LofbergH. Fixed drug eruption:an immunohistochemical investigation of the acute and healingphase. Br JDermatol1987; 116: 351± 360. 6.Breathnach SM, HintnerH. Adversedrug reactions and the skin. Oxford:Blackwell Science, 1992: 72. 7.Lee AY. Topical provocation in 31 cases of ® xeddrug eruption: changeof causative drugs in 10 years. Contact Dermatitis 1998; 38:258± 260. Fig. 2. Bullouslesion suggestive of bullouspemphigoid. Acta DermVenereol 81.
Load more

Recommended publications
  • Immune Globulin Therapy
    Immune Globulin Therapy Policy Number: Original Effective Date: MM.04.015 05/21/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 02/01/2013 Section: Prescription Drugs Place(s) of Service: Outpatient I. Description Intravenous immune globulin (IVIG) is a sterile, highly purified preparation of unmodified immunoglobulins, which are isolated from large pools of human plasma. IVIG is an infusion used to treat patients with inherited or acquired immune deficiencies. It provides passive immunity against infection by increasing a person’s antibody titer and antigen-antibody reaction potential. IVIG supplies a broad spectrum of IgG antibodies against bacterial, viral, parasitic, and mycoplasmal antigens. Subcutaneous immune globulin (Sub-q IG) is FDA approved for the treatment of patients with primary immune deficiency. It is injected under the skin using an infusion pump, which means patients can self-administer the product in a home setting. II. Criteria/Guidelines A. IVIG therapy is covered (subject to Limitations/Exclusions and Administrative Guidelines) for the following indications: 1. Treatment of primary immunodeficiencies, including: a. Congenital agammaglobulinemia ( X-linked agammaglobulinemia) b. Hypogammaglobulinemia c. Common variable immunodeficiency d. X-linked immunodeficiency with hyperimmunoglobulin M e. Severe combined immunodeficiency f. Wiskott-Aldrich syndrome 2. Idiopathic thrombocytopenic purpura (ITP) Immune Globulin Therapy 2 3. Prevention of graft-versus-host disease in non-autologous bone marrow transplant patients age 20 or older in the first 100 days after transplantation 4. Kawasaki syndrome when used in conjunction with aspirin 5. Prevention of infection in: a. HIV-infected pediatric patients b. Bone marrow transplant patients age 20 or older in the first 100 days after transplantation c.
    [Show full text]
  • Medicare Human Services (DHHS) Centers for Medicare & Coverage Issues Manual Medicaid Services (CMS) Transmittal 155 Date: MAY 1, 2002
    Department of Health & Medicare Human Services (DHHS) Centers for Medicare & Coverage Issues Manual Medicaid Services (CMS) Transmittal 155 Date: MAY 1, 2002 CHANGE REQUEST 2149 HEADER SECTION NUMBERS PAGES TO INSERT PAGES TO DELETE Table of Contents 2 1 45-30 - 45-31 2 2 NEW/REVISED MATERIAL--EFFECTIVE DATE: October 1, 2002 IMPLEMENTATION DATE: October 1, 2002 Section 45-31, Intravenous Immune Globulin’s (IVIg) for the Treatment of Autoimmune Mucocutaneous Blistering Diseases, is added to provide limited coverage for the use of IVIg for the treatment of biopsy-proven (1) Pemphigus Vulgaris, (2) Pemphigus Foliaceus, (3) Bullous Pemphigoid, (4) Mucous Membrane Pemphigoid (a.k.a., Cicatricial Pemphigoid), and (5) Epidermolysis Bullosa Acquisita. Use J1563 to bill for IVIg for the treatment of biopsy-proven (1) Pemphigus Vulgaris, (2) Pemphigus Foliaceus, (3) Bullous Pemphigoid, (4) Mucous Membrane Pemphigoid, and (5) Epidermolysis Bullosa Acquisita. This revision to the Coverage Issues Manual is a national coverage decision (NCD). The NCDs are binding on all Medicare carriers, intermediaries, peer review organizations, health maintenance organizations, competitive medical plans, and health care prepayment plans. Under 42 CFR 422.256(b), an NCD that expands coverage is also binding on a Medicare+Choice Organization. In addition, an administrative law judge may not review an NCD. (See §1869(f)(1)(A)(i) of the Social Security Act.) These instructions should be implemented within your current operating budget. DISCLAIMER: The revision date and transmittal number only apply to the redlined material. All other material was previously published in the manual and is only being reprinted. CMS-Pub.
    [Show full text]
  • ORIGINAL ARTICLE a Clinical and Histopathological Study of Lichenoid Eruption of Skin in Two Tertiary Care Hospitals of Dhaka
    ORIGINAL ARTICLE A Clinical and Histopathological study of Lichenoid Eruption of Skin in Two Tertiary Care Hospitals of Dhaka. Khaled A1, Banu SG 2, Kamal M 3, Manzoor J 4, Nasir TA 5 Introduction studies from other countries. Skin diseases manifested by lichenoid eruption, With this background, this present study was is common in our country. Patients usually undertaken to know the clinical and attend the skin disease clinic in advanced stage histopathological pattern of lichenoid eruption, of disease because of improper treatment due to age and sex distribution of the diseases and to difficulties in differentiation of myriads of well assess the clinical diagnostic accuracy by established diseases which present as lichenoid histopathology. eruption. When we call a clinical eruption lichenoid, we Materials and Method usually mean it resembles lichen planus1, the A total of 134 cases were included in this study prototype of this group of disease. The term and these cases were collected from lichenoid used clinically to describe a flat Bangabandhu Sheikh Mujib Medical University topped, shiny papular eruption resembling 2 (Jan 2003 to Feb 2005) and Apollo Hospitals lichen planus. Histopathologically these Dhaka (Oct 2006 to May 2008), both of these are diseases show lichenoid tissue reaction. The large tertiary care hospitals in Dhaka. Biopsy lichenoid tissue reaction is characterized by specimen from patients of all age group having epidermal basal cell damage that is intimately lichenoid eruption was included in this study. associated with massive infiltration of T cells in 3 Detailed clinical history including age, sex, upper dermis. distribution of lesions, presence of itching, The spectrum of clinical diseases related to exacerbating factors, drug history, family history lichenoid tissue reaction is wider and usually and any systemic manifestation were noted.
    [Show full text]
  • Bullous Pemphigoid: Trigger and Predisposing Factors
    biomolecules Review Bullous Pemphigoid: Trigger and Predisposing Factors , , Francesco Moro * y , Luca Fania * y, Jo Linda Maria Sinagra, Adele Salemme and Giovanni Di Zenzo First Dermatology Clinic, IDI-IRCCS, Via Dei Monti di Creta 104, 00167 Rome, Italy; [email protected] (J.L.M.S.); [email protected] (A.S.); [email protected] (G.D.Z.) * Correspondence: [email protected] (F.M.); [email protected] (L.F.); Tel.: +39-(342)-802-0004 (F.M.) These authors have equally contributed to the manuscript. y Received: 7 September 2020; Accepted: 8 October 2020; Published: 10 October 2020 Abstract: Bullous pemphigoid (BP) is the most frequent autoimmune subepidermal blistering disease provoked by autoantibodies directed against two hemidesmosomal proteins: BP180 and BP230. Its pathogenesis depends on the interaction between predisposing factors, such as human leukocyte antigen (HLA) genes, comorbidities, aging, and trigger factors. Several trigger factors, such as drugs, thermal or electrical burns, surgical procedures, trauma, ultraviolet irradiation, radiotherapy, chemical preparations, transplants, and infections may induce or exacerbate BP disease. Identification of predisposing and trigger factors can increase the understanding of BP pathogenesis. Furthermore, an accurate anamnesis focused on the recognition of a possible trigger factor can improve prognosis by promptly removing it. Keywords: bullous pemphigoid; autoimmune bullous disease; trigger factors; predisposing factors; etiopathogenesis 1. Introduction Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease, affecting predominantly elderly people. It is characterized by generalized pruritic urticarial plaques and tense subepithelial blisters. BP autoantibodies are directed mainly against two hemidesmosomal proteins, BP180 (also termed type XVII collagen) and BP230, which are components of the dermo-epidermal junction (DEJ) [1].
    [Show full text]
  • Bullous Pemphigoid/Pemphigus and Administration of the Pfizer/Biontech Vaccine (Comirnaty®). Introduction the Pfizer/Bionte
    Bullous Pemphigoid/Pemphigus and administration of the Pfizer/BioNTech vaccine (Comirnaty®). Introduction The Pfizer/BioNTech vaccine (Comirnaty®) is a COVID-19-mRNA-vaccine (nucleoside modified). It is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 virus, in individuals 16 years of age and older. [1] The nucleoside-modified messenger RNA in Comirnaty® is formulated in lipid nanoparticles, which enable delivery of the nonreplicating RNA into host cells to direct transient expression of the SARS-CoV-2 S antigen. The mRNA codes for membrane-anchored, full-length Spike glycoprotein with two point mutations within the central helix. [1] Comirnaty® has been registered in Europe since December 21st, 2020. Bullous skin diseases are a group of dermatoses characterized by blisters and bullae in the skin and mucous membranes. The most common are pemphigus and bullous pemphigoid (BP). Pemphigus and bullous pemphigoid are autoantibody-mediated blistering skin diseases. In pemphigus, keratinocytes in epidermis and mucous membranes lose cell-cell adhesion, and in pemphigoid, the basal keratinocytes lose adhesion to the basement membrane. Bullous pemphigoid is a more common disease than pemphigus [2]. Bullous pemphigoid is the most common heterogeneous subepidermal autoimmune blistering disease (incidence 7 per million person year) [3,4], with an increasing prevalence after the age of 70, although it can also occur in the younger. It is characterized by auto-antibodies against different structural proteins of the hemidesmosomes in the epidermal basement membrane zone (EBMZ). Bullous pemphigoid typically causes severe pruritus with predominantly cutaneous lesions consisting of tense (fluid filled) bullae, erythema, and urticarial plaques.
    [Show full text]
  • Benign Chronic Bullous Dermatosis of Childhood." Are These Immunologic Diseases?
    THE J OUItNAL OF INVEST IGATIVE DERMATOLOGY. 65:447-450, 1975 Vol. 65, No.5 Copyrig ht © 1975 by The Willia ms & Wilkins Co. Printed in U.S.A. JUVENILE DERMATITIS HERPETIFORMIS VERSUS "BENIGN CHRONIC BULLOUS DERMATOSIS OF CHILDHOOD." ARE THESE IMMUNOLOGIC DISEASES? TADEUSZ P. CHqRZELSK I, M.D., STAFANIA JABLONSKA, M .D ., ElmsT E. BEUTNER, PHD., EWA MACIEJOII'SI( A, M.D., AND MAlliA JAIlZAI3EI\ - CI-IOIlZELSKA , PHD. Department of Dermatology, Warsaw School of M edicine. Warsaw, Poland, and Department of Microbiology, State University of N ew York at Buffalo, Buffalo, N ew York , U. S. A. Seven cases of juvenile dermatitis herpetiformis have been investigated. Immunofluores­ cence a nd histologi c studies were made in all and jej unal biopsies in three. Immunopathologic results were positive in all cases including one that had previously been reported to be negative. Two groups could be distinguished according to clinical a nd histologic criteria, response to sulfapyridine, and character of the immunoglobulin depOSits. The first corresponded to dermatitis herpeti['ormis (DH) of adults, with characteristic lesions of the jejunal mucosa; the second corresponded either to bullous pemphigoid (BP), although in the majority of the cases without circulating anti basement-membrane antibodies, or to a mixed type with the combined features 0[' DH and BP. Repeated biopsies with seri al sections are essential for demonstrating immune depo its. The question arises whether any immunologically negative cases of " benign chronic bullous dermatosis of childhood" actuall y exist. In a previous paper (1] we have noted that informa tion was contributed by repeated immunologic .
    [Show full text]
  • Drug Eruptions- When to Worry
    3/17/2017 Drug reactions: Drug Eruptions‐ When to Worry 3 things you need to know 1. Type of drug reaction 2. Statistics: – Which drugs are most likely to cause that type of Lindy P. Fox, MD reaction? Associate Professor 3. Timing: Director, Hospital Consultation Service – How long after the drug started did the reaction Department of Dermatology University of California, San Francisco begin? [email protected] I have no conflicts of interest to disclose 1 Drug Eruptions: Common Causes of Cutaneous Drug Degrees of Severity Eruptions • Antibiotics Simple Complex • NSAIDs Morbilliform drug eruption Drug hypersensitivity reaction Stevens-Johnson syndrome •Sulfa (SJS) Toxic epidermal necrolysis (TEN) • Allopurinol Minimal systemic symptoms Systemic involvement • Anticonvulsants Potentially life threatening 1 3/17/2017 Morbilliform (Simple) Drug Eruption Morbilliform (Simple) Drug Eruption Per the drug chart, the most likely culprit is: Per the drug chart, the most likely culprit is: Day Day Day ‐> ‐8 ‐7 ‐6 ‐5 ‐4 ‐3 ‐2 ‐1 0 1 Day ‐> ‐8 ‐7 ‐6 ‐5 ‐4 ‐3 ‐2 ‐1 0 1 A vancomycin x x x x A vancomycin x x x x B metronidazole x x B metronidazole x x C ceftriaxone x x x C ceftriaxone x x x D norepinephrine x x x D norepinephrine x x x E omeprazole x x x x E omeprazole x x x x F SQ heparin x x x x F SQ heparin x x x x trimethoprim/ trimethoprim/ G xxxxxxx G xxxxxxx sulfamethoxazole sulfamethoxazole Admit day Rash onset Admit day Rash onset Morbilliform (Simple) Drug Eruption Drug Induced Hypersensitivity Syndrome • Begins 5‐10 days after drug started
    [Show full text]
  • Psoriasiform Drug Eruption Induced by Anti-Tuberculosis Medication: Potential Role of Plasma­ Cytoid Dendritic Cells
    Letters to the Editor 305 Psoriasiform Drug Eruption Induced by Anti-tuberculosis Medication: Potential Role of Plasma- cytoid Dendritic Cells Jae-Jeong Park1, Yoo Duk Choi2, Jee-Bum Lee1, Seong-Jin Kim1, Seung-Chul Lee1, Young Ho Won1 and Sook Jung Yun1* Departments of 1Dermatology and 2Pathology, Chonnam National University Medical School, 8 Hak-Dong, Dong-Gu, Gwangju, 501-757, Korea. *E mail: [email protected] Accepted November 23, 2009. Psoriasiform drug eruptions can be induced by several one month earlier, and treated with bicalutamide and tamsulosin drugs (1). Psoriasis is a chronic inflammatory disease hydrochloride, which were started one week after the skin eruption began. The skin lesions spread from his arms to the trunk and lower characterized by T-cell-mediated cytokine production extremities. On physical examination, erythematous papulosqua- that drives the hyperproliferation and abnormal differen- mous lesions were found, scattered on his trunk, arms, hands, legs, tiation of keratinocytes (2). Drugs can cause new lesions and buttocks (Fig. 1). Other than an elevated eosinophil count (731/ when there is no history or family history of psoriasis. mm3, normal range 0–483/mm3; 10.6%, normal range 0–7%) and Based on the psoriatic drug eruption probability score, IgE level (361 IU/ml, normal range 0–100 IU/ml), the laboratory findings were within normal limits, including a complete blood β‑blockers, synthetic anti‑malaria drugs, non‑steroidal cell count, liver and renal function tests, and urinalysis. Syphilis anti‑inflammatory drugs (NSAIDs), lithium, digoxin, and Venereal Disease Research Laboratory (VDRL) and Treponema tetracycline antibiotics are relevant in psoriasis (1, 3–5).
    [Show full text]
  • Drug Eruptions
    DRUG ERUPTIONS http://www.aocd.org A drug eruption is an adverse skin reaction to a drug. Many medications can cause reactions, especially antimicrobial agents, sulfa drugs, NSAIDs, chemotherapy agents, anticonvulsants, and psychotropic drugs. Drug eruptions can imitate a variety of other skin conditions and therefore should be considered in any patient taking medications or that has changed medications. The onset of drug eruptions is usually within 2 weeks of beginning a new drug or within days if it is due to re-exposure to a certain drug. Itching is the most common symptom. Drug eruptions occur in approximately 2-5% of hospitalized patients and in greater than 1% of the outpatient population. Adverse reactions to drugs are more prevalent in women, in the elderly, and in immunocompromised patients. Drug eruptions may be immunologically or non-immunologically mediated. There are 4 types of immunologically mediated reactions, with Type IV being the most common. Type I is immunoglobulin-E dependent and can result in anaphylaxis, angioedema, and urticaria. Type II is cytotoxic and can result in purpura. Type III reactions are immune complex reactions which can result in vasculitis and type IV is a delayed-type reaction which results in contact dermatitis and photoallergic reactions. This is important as different medications are associated with different types of reactions. For example, insulin is related with type I reactions whereas penicillin, cephalosporins, and sulfonamides cause type II reactions. Quinines and salicylates can cause type III reactions and topical medications such as neomycin can cause type IV reactions. The most common drugs that may potentially cause drug eruptions include amoxicillin, trimethoprim sulfamethoxazole, ampicillin, penicillin, cephalosporins, quinidine and gentamicin sulfate.
    [Show full text]
  • My Approach to Superficial Inflammatory Dermatoses K O Alsaad, D Ghazarian
    1233 J Clin Pathol: first published as 10.1136/jcp.2005.027151 on 25 November 2005. Downloaded from REVIEW My approach to superficial inflammatory dermatoses K O Alsaad, D Ghazarian ............................................................................................................................... J Clin Pathol 2005;58:1233–1241. doi: 10.1136/jcp.2005.027151 Superficial inflammatory dermatoses are very common and diagnosis of inflammatory skin diseases, there are limitations to this approach. The size of the comprise a wide, complex variety of clinical conditions. skin biopsy should be adequate and representa- Accurate histological diagnosis, although it can sometimes tive of all four compartments and should also be difficult to establish, is essential for clinical include hair follicles. A 2 mm punch biopsy is too small to represent all compartments, and often management. Knowledge of the microanatomy of the skin insufficient to demonstrate a recognisable pat- is important to recognise the variable histological patterns tern. A 4 mm punch biopsy is preferred, and of inflammatory skin diseases. This article reviews the non- usually adequate for the histological evaluation of most inflammatory dermatoses. However, a vesiculobullous/pustular inflammatory superficial larger biopsy (6 mm punch biopsy), or even an dermatoses based on the compartmental microanatomy of incisional biopsy, might be necessary in panni- the skin. culitis or cutaneous lymphoproliferative disor- ders. A superficial or shave biopsy should be ..........................................................................
    [Show full text]
  • Drug Eruption
    Drug eruption March 25,2015 Outline • Clinical features • Pathogenesis • How to approach? • Management? Need to know • Urticaria • Exanthematous rash • DRESS • Stevens-Johnson syndrome/TEN • Fix drug eruptions • Acute generalized exanthematous pustulosis • Photoallergic/Phototoxic. • Chemotherapy induced.. Generalized erythematous and slightly edematous maculopapular rashes Erythema and edema of face and periorbital area Investigations 28/8/47 30/8/47 2/9//47 Total 1110 1690 2024 Eosinophil SGOT 42 98 69 SGPT 130 108 88 Your Dx is D R E S S ? Drug Rash with Eosinophilia and Systemic Symptoms DRESS • Aromatic antiepileptic agents (phenytoin, carbamazepine, phenobarbital) • Sulfonamides, allopurinol, gold salts, dapsone, and minocycline. 5 days after prednisolone 30mg/d 5 days after prednisolone 30mg/d Gout after 2 weeks of allopurinol Toxic Epidermal Necrolysis from allopurinol Approach to the Acute Generalized Blistering Patient History : Onset ,underlying disease, New Drug ,other symptoms? ( fever,sore throat ) Physical examination : target lesion nikolsky sign, epidermal necrolysis, mucosal involvement Investigation : baseline lab,skin biopsy + Direct Immonofluorescence Differential diagnosis of TEN • SSSS (Staphylococcal scalded skin syndrome ) • Autoimmune blistering disease ( pemphigus,linear IgA dermatosis.. ) • Erythema multiforme Generalized exanthem Blistering ,denudation Generalized Cutaneous tenderness Nikolsky sign + desquamation Apoptosis desmoglein-1 TEN SSSS Pemphigus vulgaris Bullous pemphigoid Erythema multiforme Take
    [Show full text]
  • UC Davis Dermatology Online Journal
    UC Davis Dermatology Online Journal Title Morbilliform eruption related to eltrombopag: emerging data on the cutaneous toxicity of thrombopoietin receptor agonists Permalink https://escholarship.org/uc/item/8pk3534w Journal Dermatology Online Journal, 22(6) Authors Kazemi, Tiana Martin, Sabrina Worswick, Scott Publication Date 2016 DOI 10.5070/D3226031325 License https://creativecommons.org/licenses/by-nc-nd/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Volume 22 Number 6 June 2016 Case presentation Morbilliform eruption related to eltrombopag: emerging data on the cutaneous toxicity of thrombopoietin receptor agonists Tiana Kazemi BA1, Sabrina Martin MD2, Scott Worswick MD2 Dermatology Online Journal 22 (6): 13 1 David Geffen School of Medicine at UCLA 2 Department of Medicine, David Geffen School of Medicine at UCLA Correspondence: Scott Worswick 200 Medical Plaza Suite 450 Los Angeles CA, 90095 Tel. (310) 917-3376 [email protected] Abstract Eltrombopag is a thrombopoietin mimetic used for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenia, hepatitis C patients undergoing antiviral therapy, and thrombocytopenia secondary to aplastic anemia that is refractory to immunosuppressive therapy. We report a case of a 25-year-old man with a history of aplastic anemia who presented with fever and a monomorphic papular rash. Subsequent labs, biopsy, and clinical course favored drug-induced cutaneous toxicity, with eltrombopag as the likely culprit. Eltrombopag is generally well-tolerated; however, clinicians should be aware of the possibility of dose-independent drug-induced cutaneous toxicity with this medication. This report reviews the mechanism and use of eltrombopag along with a summary of associated adverse cutaneous reactions.
    [Show full text]